Chemical combination effects predict connectivity in biological systems
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Efforts to construct therapeutically useful models of biological systems require large and diverse sets of data on functional connections between their components. Here we show that cellular responses to combinations of chemicals reveal how their biological targets are connected. Simulations of pathways with pairs of inhibitors at varying doses predict distinct response surface shapes that are reproduced in a yeast experiment, with further support from a larger screen using human tumour cells. The response morphology yields detailed connectivity constraints between nearby targets, and synergy profiles across many combinations show relatedness between targets in the whole network. Constraints from chemical combinations complement genetic studies, because they probe different cellular components and can be applied to disease models that are not amenable to mutagenesis. Chemical probes also offer increased flexibility, as they can be continuously dosed, temporally controlled, and readily combined. After extending this initial study to cover a wider range of combination effects and pathway topologies, chemical combinations may be used to refine network models or to identify novel targets. This response surface methodology may even apply to non-biological systems where responses to targeted perturbations can be measured.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1707]
Experimental — accuracy not yet measuredIn the citing paper
“and that on general grounds [1706-1708,2142] such a strategy (for instance of combining a cell-permeable iron chelator with a cell-permeable antioxidant) might be expected to give a synergistic response.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1707]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Numerical recipes in C: the art of scientific computing
(1993) · Choice Reviews Online · doi:10.5860/choice.30-5638 · Cited by 17,933
David, F. N., & Tukey, J. W. (1977) · Biometrics · doi:10.2307/2529486 · Cited by 12,708
Network motifs: simple building blocks of complex networks.
Milo, R., Shen-Orr, S., Itzkovitz, S., Kashtan, N., Chklovskii, D., & Alon, U. (2002) · Science · doi:10.1126/science.298.5594.824 · Cited by 7,368 · cited 2×
“Finally, because the simulated combination responses were insensitive to the reaction details, this methodology may even be extendable to non-biological network problems where responses to targeted perturbations can be measured (Milo et al , 2002).”
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683 · cited 1×
“…Saccharomyces cerevisiae (Zhang et al , 2005), which are built upon protein–DNA (Lee et al , 2002) and protein–protein (Ho et al , 2002) associations, supplemented by correlated changes in gene expression (Hughes et al , 2000) or protein abundances (Gygi et al , 1999) under differing conditions.”
BioGRID: a general repository for interaction datasets
Stark, C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj109 · Cited by 3,960 · cited 2×
“The observed synergies between sterol inhibitors are reflected in homozygous synthetic lethalities (Stark et al , 2006) that are internal to the pathway, and rapamycin’s synergy with terbinafine agrees with the reported interaction between TOR1 and ERG1.”
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry
Ho, Y., Gruhler, A., Heilbut, A., Bader, G. D., Moore, L., Adams, S.-L., Millar, A., Taylor, P., Bennett, K., Boutilier, K., et al. (2002) · Nature · doi:10.1038/415180a · Cited by 3,601
Self-citationIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
Functional Discovery via a Compendium of Expression Profiles
Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour, C. D., Bennett, H. A., Coffey, E., Dai, H., He, Y. D., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00015-5 · Cited by 2,533
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Cited by
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“Consider an extreme scenario in which the drug combination barely reaches significance (e.g., P = 0.049) and its individual components narrowly failed to reach significance (e.g., P = 0.051).”
BackgroundMethodInfluentialCombinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Self-citationStructure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy
Ejim, L., Farha, M. A., Falconer, S. B., Wildenhain, J., Coombes, B. K., Tyers, M., Brown, E. D., & Wright, G. D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.559 · Cited by 525
Mathews Griner, L. A., Guha, R., Shinn, P., Young, R. M., Keller, J. M., Liu, D., Goldlust, I. S., Yasgar, A., McKnight, C., Boxer, M. B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311846111 · Cited by 377
A blend of small molecules regulates both mating and development in Caenorhabditis elegans
Srinivasan, J., Kaplan, F., Ajredini, R., Zachariah, C., Alborn, H. T., Teal, P. E. A., Malik, R. U., Edison, A. S., Sternberg, P. W., & Schroeder, F. C. (2008) · Nature · doi:10.1038/nature07168 · Cited by 364
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…et al. 2007; Goltsov et al. 2009; Hegreness et al. 2008; Huang et al. 2008b; Jia et al. 2009; Koufaki et al. 2009; Kuhn et al. 2010; Lee et al. 2007; Lehár et al. 2007, 2008a, b; Li et al. 2007; Liby et al. 2007; Morphy and Rankovic 2007; Pachauri et al. 2009; Reznichenko et al. 2010; Sarkar…”
Drug interactions and the evolution of antibiotic resistance
Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2133 · Cited by 350
Duarte, D., & Vale, N. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100110 · Cited by 340
Systematic exploration of synergistic drug pairs
Cokol, M., Chua, H. N., Tasan, M., Mutlu, B., Weinstein, Z. B., Suzuki, Y., Nergiz, M. E., Costanzo, M., Baryshnikova, A., Giaever, G., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.71 · Cited by 315
The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Antagonism between Bacteriostatic and Bactericidal Antibiotics Is Prevalent
Ocampo, P. S., Lázár, V., Papp, B., Arnoldini, M., Abel zur Wiesch, P., Busa-Fekete, R., Fekete, G., Pál, C., Ackermann, M., & Bonhoeffer, S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02463-14 · Cited by 284
NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning
Chen, X., Ren, B., Chen, M., Wang, Q., Zhang, L., & Yan, G. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004975 · Cited by 279
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution
Bollenbach, T. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.05.008 · Cited by 261
Pharmacodynamic Drug–Drug Interactions
Niu, J., Straubinger, R. M., & Mager, D. E. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1434 · Cited by 250
Combination drugs, an emerging option for antibacterial therapy
Cottarel, G., & Wierzbowski, J. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.09.004 · Cited by 237
Applications of Connectivity Map in drug discovery and development
Qu, X. A., & Rajpal, D. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.017 · Cited by 235
Nonoptimal microbial response to antibiotics underlies suppressive drug interactions
Bollenbach, T., Quan, S., Chait, R., & Kishony, R. (2009) · Cell · doi:10.1016/j.cell.2009.10.025 · Cited by 227
Combinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
Bulusu, K. C., Guha, R., Mason, D. J., Lewis, R. P. I., Muratov, E., Kalantar Motamedi, Y., Cokol, M., & Bender, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.003 · Cited by 202
An integrated platform of genomic assays reveals small-molecule bioactivities
Hoon, S., M Smith, A., Wallace, I. M., Suresh, S., Miranda, M., Fung, E., Proctor, M., Shokat, K. M., Zhang, C., Davis, R. W., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.100 · Cited by 201
Rubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200
“Dose-matrix plots of these data (lower panels of Figure S9a,b,e,f in Additional file 10) are best described by a highest single agent- or Bliss-like masking model in which dual inhibition of targets across two intersecting pathways is required for full inhibition [29].”
BackgroundModels from experiments: combinatorial drug perturbations of cancer cells
Nelander, S., Wang, W., Nilsson, B., She, Q., Pratilas, C., Rosen, N., Gennemark, P., & Sander, C. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.53 · Cited by 187
Finding multiple target optimal intervention in disease‐related molecular network
Yang, K., Bai, H., Ouyang, Q., Lai, L., & Tang, C. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.60 · Cited by 186
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Tang, J., & Aittokallio, T. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990470 · Cited by 175
Lehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172
Self-citationA compendium of kinetic modulatory profiles identifies ferroptosis regulators
Conlon, M., Poltorack, C. D., Forcina, G. C., Armenta, D. A., Mallais, M., Perez, M. A., Wells, A. C., Kahanu, A., Magtanong, L., Watts, J. L., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00751-4 · Cited by 155
The physiology and genetics of bacterial responses to antibiotic combinations
Roemhild, R., Bollenbach, T., & Andersson, D. I. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00700-5 · Cited by 160
Microfluidics Using Spatially Defined Arrays of Droplets in One, Two, and Three Dimensions
Pompano, R. R., Liu, W., Du, W., & Ismagilov, R. F. (2011) · Annual Review of Analytical Chemistry · doi:10.1146/annurev.anchem.012809.102303 · Cited by 144
Fröhlich, F., Kessler, T., Weindl, D., Shadrin, A., Schmiester, L., Hache, H., Muradyan, A., Schütte, M., Lim, J.-H., Heinig, M., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.013 · Cited by 143
“04) and highest single agent (Lehár et al., 2007) (HSA) model (r = 0.”
BackgroundKaranam, N. K., Srinivasan, K., Ding, L., Sishc, B., Saha, D., & Story, M. D. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.136 · Cited by 136
Synergistic and Antagonistic Drug Combinations Depend on Network Topology
Yin, N., Ma, W., Pei, J., Ouyang, Q., Tang, C., & Lai, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093960 · Cited by 139
“biological network involving the drug targets under study may shed light into the way the drugs act [16–18] and interact [19,20].”
BackgroundResultInfluentialMechanism-independent method for predicting response to multidrug combinations in bacteria
Wood, K., Nishida, S., Sontag, E. D., & Cluzel, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201281109 · Cited by 135
Towards genome-scale signalling-network reconstructions
Hyduke, D. R., & Palsson, B. Ø. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2750 · Cited by 139
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
Dafflon, C., Craig, V. J., Méreau, H., Gräsel, J., Engstler, B. S., Hoffman, G., Nigsch, F., Gaulis, S., Barys, L., Ito, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.327 · Cited by 126
Systems approaches and algorithms for discovery of combinatorial therapies
Feala, J. D., Cortes, J., Duxbury, P. M., Piermarocchi, C., McCulloch, A. D., & Paternostro, G. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.51 · Cited by 96
Lee, M. S., Johansen, L., Zhang, Y., Wilson, A., Keegan, M., Avery, W., Elliott, P., Borisy, A. A., & Keith, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2235 · Cited by 115
Self-citationHarnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
El‐Hafeez, T. A., Shams, M. Y., Elshaier, Y. A. M. M., Farghaly, H. M., & Hassanien, A. E. (2024) · Scientific Reports · doi:10.1038/s41598-024-52814-w · Cited by 114
Yeast chemical genomics and drug discovery: an update
Hoon, S. S., St.Onge, R. P., Giaever, G. N., & Nislow, C. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.07.006 · Cited by 110
Gao, Y., Li, S., Wang, J., Luo, C., Zhao, S., & Zheng, N. (2017) · Toxins · doi:10.3390/toxins10010013 · Cited by 104
Karanam, N. K., Ding, L., Asaithamby, A., & Story, M. D. (2019) · Translational research · doi:10.1016/j.trsl.2019.10.003 · Cited by 107
Farha, M. A., Czarny, T. L., Myers, C. L., Worrall, L. J., French, S., Conrady, D. G., Wang, Y., Oldfield, E., Strynadka, N. C. J., & Brown, E. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511751112 · Cited by 104
Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses
Geva‐Zatorsky, N., Dekel, E., Cohen, A., Danon, T., Cohen, L., & Alon, U. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.011 · Cited by 111
Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition
Lederer, S., Dijkstra, T. M. H., & Heskes, T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00031 · Cited by 103
Optimization of drug combinations using Feedback System Control
Nowak-Sliwinska, P. M., Weiss, A., Ding, X., Dyson, P. J., van den Bergh, H., Griffioen, A. W., & Ho, C. (2016) · Nature Protocols · doi:10.1038/nprot.2016.017 · Cited by 105
Targeting and tinkering with interaction networks
Russell, R. B., & Aloy, P. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.119 · Cited by 104
Interplay between Sucrose and Folate Modulates Auxin Signaling in Arabidopsis
Stokes, M. E., Chattopadhyay, A., Wilkins, O., Nambara, E., & Campbell, M. M. (2013) · PLANT PHYSIOLOGY · doi:10.1104/pp.113.215095 · Cited by 105
Guimerà, R., & Sales‐Pardo, M. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003374 · Cited by 101
Network modeling of the transcriptional effects of copy number aberrations in glioblastoma
Jörnsten, R., Abenius, T., Kling, T., Schmidt, L., Johansson, E., Nordling, T. E. M., Nordlander, B., Sander, C., Gennemark, P., Funa, K., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.17 · Cited by 89
High‐order combination effects and biological robustness
Lehár, J., Krueger, A., Zimmermann, G. R., & Borisy, A. A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.51 · Cited by 101
Self-citationKell, D. B., & Pretorius, E. (2016) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2016.08.006 · Cited by 95
Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0852 · Cited by 90
“Todetermine whether the combination benefit of MEK and SHP2 inhibitors is additive or synergistic, we performed a cell proliferation assay using an 8 by 8 combination dose matrix of selumetinib and SHP099 inMIAPaCa-2 andHUP-T3 cells and assessed the synergy using the Loewe Excess method (41).”
MethodA cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
Narayan, R. S., Molenaar, P., Teng, J., Cornelissen, F. M. G., Roelofs, I., de Menezes, R. X., Dik, R., Lagerweij, T., Broersma, Y., Petersen, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16735-2 · Cited by 94
Lyu, Y., Yang, X., Goswami, S., Gorityala, B. K., Idowu, T., Domalaon, R., Zhanel, G. G., Shan, A., & Schweizer, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01742 · Cited by 92
Systematic analysis of drug combinations against Gram-positive bacteria
Cacace, E., Kim, V., Varik, V., Knopp, M. R., Tietgen, M., Brauer-Nikonow, A., İnecik, K., Mateus, A., Milanese, A., Mårli, M. T., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01486-9 · Cited by 86
Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application
Calzetta, L., Page, C. P., Matera, M. G., Cazzola, M., & Rogliani, P. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000951 · Cited by 82
Monahan, L. G., Turnbull, L., Osvath, S. R., Birch, D., Charles, I. G., & Whitchurch, C. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01901-13 · Cited by 91
Chemogenomic profiling predicts antifungal synergies
Jansen, G., Lee, A. Y., Epp, E., Fredette, A., Surprenant, J., Harcus, D., Scott, M. S., Tan, E., Nishimura, T., Whiteway, M. S., et al. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.95 · Cited by 84
Ravindranathan, P., Pasham, D., Balaji, U., Cardenas, J., Gu, J., Toden, S., & Goel, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-32267-8 · Cited by 79
Huang, L., Jiang, Y., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/srep40752 · Cited by 84
Prediction of disease–gene–drug relationships following a differential network analysis
Zickenrott, S., Angarica, V. E., Upadhyaya, B. B., & del Sol, A. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.393 · Cited by 86
Additive dose response models: defining synergy
Lederer, S., Dijkstra, T. M. H., & Heskes, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01384 · Cited by 74
Systems Biology Brings New Dimensions for Structure-Based Drug Design
Pei, J., Yin, N., Ma, X., & Lai, L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504810z · Cited by 81
Using a newly introduced framework to measure ecological stressor interactions
Tekin, E., Diamant, E. S., Cruz‐Loya, M., Enriquez, V., Singh, N. P., Savage, V. M., & Yeh, P. J. (2020) · Ecology Letters · doi:10.1111/ele.13533 · Cited by 75
Network based elucidation of drug response: from modulators to targets
Iorio, F., Sáez-Rodríguez, J., & di Bernardo, D. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-139 · Cited by 75
Brach, D., Johnston-Blackwell, D., Drew, A., Lingaraj, T., Motwani, V., Warholic, N. M., Feldman, I., Plescia, C., Smith, J. J., Copeland, R. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0840 · Cited by 70
Toward precision medicine of breast cancer
Carels, N., Spinassé, L. B., Tilli, T. M., & Tuszyński, J. A. (2016) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-016-0035-4 · Cited by 70
Mukherjee, P. K., Banerjee, S., & Kar, A. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-020-09730-4 · Cited by 69
Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment
Birnboim-Perach, R., & Benhar, I. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93697 · Cited by 61
Ulrich-Merzenich, G. S. (2014) · Synergy · doi:10.1016/j.synres.2014.07.011 · Cited by 65
A review on graph neural networks for predicting synergistic drug combinations
Besharatifard, M., & Vafaee, F. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-023-10669-z · Cited by 68
Unconventional screening approaches for antibiotic discovery
Farha, M. A., & Brown, E. D. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12803 · Cited by 60
Carita, G., Frisch-Dit-Leitz, E., Dahmani, A., Raymondie, C., Cassoux, N., Piperno-Neumann, S., Némati, F., Laurent, C., de Koning, L., Halilovic, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9552 · Cited by 58
MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
Booher, R. N., Hatch, H., Dolinski, B. M., Nguyen, T. P., Harmonay, L., Al-Assaad, A.-S., Ayers, M., Nebozhyn, M., Loboda, A. P., Hirsch, H. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108371 · Cited by 65
Bianchi, M. T., Pathmanathan, J. S., & Cash, S. S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.049 · Cited by 59
Uncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells
Wood, K. B., Wood, K. C., Nishida, S., & Cluzel, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.007 · Cited by 61
Genetics and iron in the systems biology of Parkinson’s disease and some related disorders
Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.11.015 · Cited by 54
Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance
Fröhlich, F., Gerosa, L., Muhlich, J. L., & Sorger, P. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202210988 · Cited by 55
Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine
Antman, E. M., Weiss, S. T., & Loscalzo, J. (2012) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1173 · Cited by 54
Systems Biology Approaches and Tools for Analysis of Interactomes and Multi-target Drugs
Schrattenholz, A. S., Groebe, K., & Šoškić, V. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-800-3_2 · Cited by 55
Kell, D. B. (2007) · IUBMB Life · doi:10.1080/15216540701694252 · Cited by 52
Hiss, D. C., Gabriels, G. A., & Folb, P. I. (2007) · Cancer Cell International · doi:10.1186/1475-2867-7-5 · Cited by 61
Jin, G., Zhao, H., Zhou, X., & Wong, S. T. C. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr202 · Cited by 56
Friedman, A. A., Amzallag, A., Pruteanu-Malinici, I., Baniya, S., Cooper, Z. A., Piris, A., Hargreaves, L., Igras, V., Frederick, D. T., Lawrence, D. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140310 · Cited by 56
Šrůtová, K., Čuřík, N., Burda, P., Savvulidi, F. G., Silvestri, G., Trotta, R., Klamová, H., Pecherková, P., Sovová, Ž., Koblihova, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.193086 · Cited by 49
Subramaniam, S., Raja, M. R. K., & Sivasubramanian, A. (2014) · Revista Brasileira de Farmacognosia · doi:10.1590/0102-695x20142413348 · Cited by 57
Voigt, E. A., & Yin, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0008 · Cited by 50
Wood, K. B., & Cluzel, P. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-48 · Cited by 51
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Cheraghchi-Bashi-Astaneh, A., Coker, E. A., Bulusu, K. C., Jaaks, P., Crafter, C., Lightfoot, H. W., Milo, M., McCarten, K., Jenkins, D. F., van der Meer, D. J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0388 · Cited by 48
Lu, H., Liu, C., Huynh, H., Le, T. B. U., LaMarche, M. J., Mohseni, M., Engelman, J. A., Hammerman, P. S., Caponigro, G., & Hao, H.-X. (2020) · Oncotarget · doi:10.18632/oncotarget.27435 · Cited by 43
Chemogenetic fingerprinting by analysis of cellular growth dynamics
Warringer, J., Anevski, D., Liu, B., & Blomberg, A. (2008) · BMC Chemical Biology · doi:10.1186/1472-6769-8-3 · Cited by 46
Brnjic, S., Olofsson, M. H., Havelka, A. M., & Linder, S. T. (2010) · Molecular BioSystems · doi:10.1039/b920805d · Cited by 49
From additivity to synergism – A modelling perspective
Ritz, C., & Streibig, J. C. (2014) · Synergy · doi:10.1016/j.synres.2014.07.010 · Cited by 43
Mason, D. J., Eastman, R. T., Lewis, R. P. I., Stott, I. P., Guha, R., & Bender, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01096 · Cited by 42
Metadata
- Authors
- Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., Lee, M. S., Borisy, A. A., Stockwell, B. R., & Keith, C. T.
- Affiliations
- Boston University (US)
- Columbia University (US)
- Corresponding author
- Lehár, Joseph
- Venue
- Molecular Systems Biology
- Published
- 2007-02-27
- Volume
- 3
- Issue
- 1
- Pages
- 80-80
- ISSN
- 1744-4292 (ISSN-L)
- PMC
- PMC1828746
- OpenAlex
- W1975728616
- Cited by
- 275
- References
- 68
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 15 · 2023: 15 · 2022: 9 · 2021: 14 · 2020: 11 · 2019: 17 · 2018: 18 · 2017: 11 · 2016: 15 · 2015: 18 · 2014: 22 · 2013: 14 · 2012: 13
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Systems Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OpenBU (Boston University) (submittedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- synergistic effect, response surface, pathway modeling, inhibitors, dose-response relationship, yeast, cancer cells, network inference, chemical probes
- MeSH terms
- Computer Simulation, Drug Combinations, Drug Synergism, Humans, Models, Biological, Saccharomyces cerevisiae, Sterols, Models, Statistical, Gene Expression Regulation, Fungal, HCT116 Cells, Systems Biology, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.